Millar to Acquire Sentron, Maker of Pressure and pH Sensors

Millar, a developer of pressure sensor enabled medical devices, has begun a deal to acquire Sentron, a Netherlands-based pressure and pH sensor manufacturing company (currently owned by Wellinq).
 
Millar said the intended acquisition aligns with its commitment to advance medical understanding and enable scientific discoveries through pressure sensor technology. The company also says the transaction will help it to redefine the landscape of medical sensor technology.
 
“We are thrilled to welcome Sentron into the Millar family,” Millar president and CEO  Tim Daugherty told the press. “With over five decades of expertise, Millar has been at the forefront of pressure sensor technology. This acquisition is not just a strategic business move; it’s a transformative leap into a future where innovation knows no bounds. Sentron’s technologies and manufacturing capabilities perfectly complement our own, enabling us to offer an even broader spectrum of solutions to our clients worldwide.”
 
The company said the deal will establish Millar as a one-stop-shop for sensor development, from raw components to commercialized, sensor-enabled devices. The company will gain sensor development and fabrication facilities from Sentron, as well as broaden its offerings to include pH and electrical conductivity sensors.
 
Once the acquisition is complete, Sentron will become a wholly-owned Millar subsidiary. The deal is expected to close by the end of 2023.
 
Sander Hartman, CEO of Wellinq, said, “Joining forces with Millar represents a monumental step for Sentron. Millar’s reputation for excellence and their unwavering commitment to advancing medical research aligns perfectly with our own values. Sentron’s facilities and expertise, combined with Millar’s legacy of innovation, will undoubtedly pave the way for groundbreaking advancements in medical sensor technology. Additionally, we are looking forward to the opportunity to contribute to Millar’s Board of Directors, leveraging our unique capabilities and extensive network to expand our reach and make a larger impact on patient outcomes.”